Technical Analysis for IMMX - Immix Biopharma, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Support | Bullish | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 0.00% | |
Volume Surge | Other | 0.00% | |
Outside Day | Range Expansion | 0.00% | |
Up 3 Days in a Row | Strength | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
20 DMA Support | Bullish | 7.06% | |
Pocket Pivot | Bullish Swing Setup | 7.06% | |
Inside Day | Range Contraction | 7.06% | |
BB Squeeze Ended | Range Expansion | 7.06% |
Alert | Time |
---|---|
Upper Bollinger Band Resistance | about 18 hours ago |
Up 10% | about 21 hours ago |
Up 1 ATR | about 21 hours ago |
60 Minute Opening Range Breakout | about 21 hours ago |
Rose Above Upper Bollinger Band | about 21 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/28/2024
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. It is developing IMX-110 that is in Phase Ib/IIa clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. The company has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase Ib clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc. was incorporated in 2012 and is based in Los Angeles, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Autoimmune Disease Inflammation Colorectal Cancer Sarcoma Ulcerative Colitis Abdominal Pain Crohn's Disease Soft Tissue Sarcoma
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Autoimmune Disease Inflammation Colorectal Cancer Sarcoma Ulcerative Colitis Abdominal Pain Crohn's Disease Soft Tissue Sarcoma
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 7.75 |
52 Week Low | 1.26 |
Average Volume | 118,911 |
200-Day Moving Average | 2.22 |
50-Day Moving Average | 1.63 |
20-Day Moving Average | 1.67 |
10-Day Moving Average | 1.71 |
Average True Range | 0.16 |
RSI (14) | 58.85 |
ADX | 20.34 |
+DI | 28.97 |
-DI | 14.23 |
Chandelier Exit (Long, 3 ATRs) | 1.48 |
Chandelier Exit (Short, 3 ATRs) | 1.95 |
Upper Bollinger Bands | 1.83 |
Lower Bollinger Band | 1.50 |
Percent B (%b) | 0.96 |
BandWidth | 19.73 |
MACD Line | 0.02 |
MACD Signal Line | 0.01 |
MACD Histogram | 0.0113 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.25 | ||||
Resistance 3 (R3) | 2.24 | 2.08 | 2.18 | ||
Resistance 2 (R2) | 2.08 | 1.97 | 2.09 | 2.15 | |
Resistance 1 (R1) | 1.95 | 1.91 | 2.02 | 1.96 | 2.13 |
Pivot Point | 1.80 | 1.80 | 1.83 | 1.80 | 1.80 |
Support 1 (S1) | 1.67 | 1.69 | 1.73 | 1.68 | 1.51 |
Support 2 (S2) | 1.51 | 1.62 | 1.52 | 1.49 | |
Support 3 (S3) | 1.38 | 1.51 | 1.46 | ||
Support 4 (S4) | 1.39 |